Blog

Roberto Borea: Utilizing ctDNA in mechanisms of resistance to targeted therapies in patients with metastatic NSCLC

Roberto Borea/X

Mar 19, 2025, 05:01

Roberto Borea: Utilizing ctDNA in mechanisms of resistance to targeted therapies in patients with metastatic NSCLC

Roberto Borea, PhD student at The University of Genoa, shared a paper Sophie M. Ernst and colleagues authored on X:

“Out in Nature Reviews Clinical Oncology:

– ctDNA helps uncover resistance mechanisms to targeted therapies
– Standardized protocols are crucial for improving applications
– ctDNA + tissue provides a more comprehensive view.”

Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials

Authors: Sophie M. Ernst et al.

Roberto Borea

Adrianus J de Langen Anne-Marie C. Dingemans Benjamin Besse cancer Christian Rolfo Egbert F. Smit Hendrikus J. Dubbink Jan H. von der Thüsen Joachim G.J.V. Aerts Jordi Remon Laura Mezquita Marthe S. Paats Mihaela Aldea OncoDaily Oncology Roberto Borea Sanjay Popat Sophie M. Ernst

Oncologist Near Me - Douglas Flora: Pioneering AI Integration in Cancer Care

Douglas Hanahan was Honored with the 2025 Pezcoller Foundation-AACR International Award for Extraordinary Cancer Research

Bente Mikkelsen Appointed as Director of Global Engagement Strategies at St. Jude Children's Research Hospital

Audrey Evans - mother of neuroblastoma, a force for good in the world

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer